Printer Friendly

New Book Addresses Issues In Relation To Existing Vaccine Adjuvants, Those In Clinical Trials, And Those Still at a Pre-Clinical Stage.

DUBLIN, Ireland -- Research and Markets ( has announced the addition of Vaccine Adjuvants and Delivery Systems to their offering.

The authoritative reference on recent developments in vaccinology

New technologies, including recombinant protein and DNA, have sparked advances in vaccine development and delivery systems. This book addresses these issues in relation to existing vaccine adjuvants, those in clinical trials, and those still at a pre-clinical stage. It includes coverage of the current state of the adjuvant field and developing formulation methods. From an overview of vaccine adjuvant development and safety, the book progresses to describe different types of systems and therapies before concluding with a look at the future of vaccine delivery.

With chapters written by leading experts in their fields, Vaccine Adjuvants and Delivery Systems:

- Provides a comprehensive overview of the rapidly evolving field and developing formulation methods

- Covers cutting-edge technologies and gives the current status of adjuvants in clinical trials and those still in the pre-clinical stage

- Includes detailed information on specific vaccine adjuvants, including MF59, TLR4 agonists, new iscoms, cytokines, polyphosphazenes, and more

- Provides a historical perspective on the development of vaccine adjuvants and discusses the mechanisms of adjuvant actions

- Covers some novel adjuvants and delivery systems and the safety evaluation of adjuvants

A great reference for researchers, scientists, and students in vaccinology, biotechnology, immunology, and molecular biology, this resource is also valuable for researchers and scientists in veterinary medicine who work to prevent diseases in animals.

About the author:

MANMOHAN SINGH, M.Pharm., PhD, has worked in the area of vaccine adjuvants and delivery systems for seventeen years and has authored over eighty-five manuscripts and review articles. Dr. Singh is on the editorial board of five international journals and has contributed several book chapters. He is a Director of Vaccine Research within Novartis Vaccines

Content Outline:



Chapter 1. Development of vaccine adjuvants - a historical perspective (Gary Ott and Gary Van Nest).

Chapter 2. Antigen-Processing and Presentation (Subash Sad).

Chapter 3. Mechanisms of Adjuvant Action (Nils Lycke).

Chapter 4. Aluminum-containing Adjuvants: Properties, Formulation and Use (Stanley L. Hem and Harm HogenEsch).

Chapter 5. MF59: A Safe and Potent Oil in Water Emulsion Adjuvant (D.T. O'Hagan).

Chapter 6. TLR4 agonists as vaccine adjuvants (David A. Johnson and Jory R. Baldridge).

Chapter 7. Immunostimulatory CpG Oligodeoxynucleotides as Vaccine Adjuvants (Dennis M. Klinman, Debbie Currie and Hidekazu Shirota).

Chapter 8. Small Molecule Immunopotentiators as Vaccine Adjuvants (Fengfeng Xu, Nicholas M. Valiante, and Jeffrey B. Ulmer).

Chapter 9. New ISCOMs Meet Unsettled Vaccine Demands (Bror Morein, Kefei Hu, Karin Lovgren, and Erik Dhondt).

Chapter 10. Surface Charged Poly(lactide-co-glycolide) Microparticles as Novel Antigen Delivery Systems (Manmohan Singh, James Chesko, Jina Kazzaz and Derek T. O'Hagan).

Chapter 11. Liposomal Cytokines and Liposomes Targeted to Costimulatory Molecules as Adjuvants for HIV Subunit Vaccines (Bulent Ozpolat and Lawrence B. Lachman).

Chapter 12. Archaeosomes Vaccine Adjuvants for Cross-priming CD8+ T Cell Immunity (Lakshmi Krishnan and G. Dennis Sprott).

Chapter 13 Mucosal Adjuvants and Delivery Systems (Michael Vajdy).

Chapter 14. Cytokines as Vaccine Adjuvants (Nejat Egilmez).

Chapter 15. Polyphosphazenes as vaccine adjuvants (Alexander K. Andrianov).

Chapter 16. Vaccine Delivery by Transdermal Electroporation (Amit Misra).

Chapter 17. Nonclinical Safety Assessment of Vaccines, and the Evaluation of Novel Adjuvants and Delivery Systems (Jose A. Lebron, Jayanthi J. Wolf, Catherine V. Kaplanski, and Brian J. Ledwith).

Chapter 18. Safety Evaluation of Vaccine Adjuvants (Erik B. Lindblad).

For more information visit
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Oct 26, 2007
Previous Article:Research and Markets: If the Biosimilar Industry is Going to Progress beyond the First Generation Biologics Then It Needs to Target More High Profile...
Next Article:Research and Markets: The Essilor International Strategic Analysis Profile Examines Essilor International's Business Structure and Operations,...

Related Articles
Summit plans industrial development for 42-acre former Coca Cola site.
C&W notches up 60,000 s/f in deals at Overlook in six months.
Open house slated for state's largest Class A complex.
Klingmann launches Brandscapes book.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters